Your browser doesn't support javascript.
loading
Rates of False-Negative Screening in Prostate Specific Antigen Secondary to 5-Alpha Reductase Inhibitor Usage: A Quality-Improvement Initiative
Loloi, Justin; Wei, Matthew; Babar, Mustufa; Zhu, Denzel; Fram, Ethan B.; Maria, Pedro.
  • Loloi, Justin; Albert Einstein College of Medicine. Montefiore Medical Center. Department of Urology. Bronx. US
  • Wei, Matthew; Albert Einstein College of Medicine. Bronx. US
  • Babar, Mustufa; Albert Einstein College of Medicine. Bronx. US
  • Zhu, Denzel; Albert Einstein College of Medicine. Bronx. US
  • Fram, Ethan B.; Albert Einstein College of Medicine. Montefiore Medical Center. Department of Urology. Bronx. US
  • Maria, Pedro; Albert Einstein College of Medicine. Montefiore Medical Center. Department of Urology. Bronx. US
Int. braz. j. urol ; 48(4): 688-695, July-Aug. 2022. tab, graf
Article in English | LILACS-Express | LILACS | ID: biblio-1385145
ABSTRACT
ABSTRACT Purpose Patients often take 5-alpha reductase inhibitors (5-ARIs) for the management of benign prostatic hyperplasia. However, 5-ARIs can decrease prostate specific antigen (PSA) by approximately half and therefore may lead to false negative PSA tests. We investigated false-screening rates in men on 5-ARIs undergoing PSA testing and whether ordering physicians noticed false negative findings. Materials and Methods A single institution, retrospective study was conducted on patients with a PSA value documented between 2014 and 2017. Patient demographics, PSA results, 5-ARI usage, and providing clinician characteristics were collected. Published normal PSA values were used to determine PSA test positivity; values for those on 5-ARIs were doubled. Results A total of 29,131 men were included. 1,654 (5.7%) were prescribed 5-ARIs at least 12 months prior to PSA evaluation. 118 men (7.1%) had a value that would be positive if corrected for 5-ARI usage, 33 (27.9%) of which had no indication that the provider had noted this. There was no effect on rates of false negative values if the PSA was ordered by a different provider than the one who prescribed the 5-ARI (p = 0.837). However, if the provider who ordered the PSA test was an urologist, the likelihood that a false negative value would be identified was lower (p=0.001). Conclusions More than a quarter of men with false negative tests were missed. This occurred more often when the ordering provider was not an urologist. An educational opportunity exists to improve the quality of PSA testing by preventing false negative tests.


Full text: Available Index: LILACS (Americas) Type of study: Diagnostic study / Observational study / Prognostic study / Screening study Language: English Journal: Int. braz. j. urol Journal subject: Urology Year: 2022 Type: Article Affiliation country: United States Institution/Affiliation country: Albert Einstein College of Medicine/US

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Type of study: Diagnostic study / Observational study / Prognostic study / Screening study Language: English Journal: Int. braz. j. urol Journal subject: Urology Year: 2022 Type: Article Affiliation country: United States Institution/Affiliation country: Albert Einstein College of Medicine/US